RESEARCH TRIANGLE PARK – Japan-based Fujifilm could announce the Research Triangle as the site for a massive, new $2 billion biotech manufacturing site as early as Thursday morning.
Fujuifilm already has a significant presence in Morrisville through its subsidiary Fujifilm Diosynth Biotechnologies.
However, no immediate plans are in place for an announcement of the location, a Fujifilm spokesperson told Sarah Krueger of WRAL TV. The site may not be announced until May or June, Krueger was told.
North Carolina’s Economic Development Committee, which considers tax incentives for corporate expansions and facilities, has a meeting in Raleigh at 11 a.m. So far the N.C. Department of Commerce has only said that projects will be reviewed by the committee.
Share this article
Share this article
TOKYO, Jan. 6, 2021 /PRNewswire/ FUJIFILM Corporation (President: Kenji Sukeno) is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, with development and manufacturing facilities across the U.S.A., U.K., and Denmark will operate the new facility. This new facility will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand. In addition to drug substance manufacture, the facility will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services. The new site will be built within
Fujifilm to invest $2bn to build large-scale cell culture manufacturing site pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
Fujifilm to invest over $2bn to build large scale US cell culture facility Tokyo headquartered, Fujifilm Corporation, has announced a new US$2bn (£1.4bn/€1.5bn) investment to establish a new large-scale biopharma site in the US.
The facility will be operated by its subsidiary, Fujifilm Diosynth Biotechnologies, which has locations in Teesside, UK, in North Carolina and Texas in the US and in Hillerød, Denmark.
The move serves to further underline Fujiflim’s ambitions within the contract development and manufacturing (CDMO) space, following its US$928m investment, announced last year, to expand its site in Hillerød, Denmark, and the capital it is ploughing into its UK and US facilities.
This news release is issued by FUJIFILM Corporation in Japan.
Fujifilm makes no representation that products on this news release are commercially available in all countries and regions（including US and EU). Approved uses of healthcare products vary by country and region.
Specifications and appearance of products are subject to change without notice.
TOKYO, December 17, 2020 ― FUJIFILM Corporation (President: Kenji Sukeno) is pleased to announce that it has filed an application with the Pharmaceuticals and Medical Devices Agency to obtain manufacturing and marketing approval for a rapid and simple antigen test kit for detecting SARS-CoV-2, using silver amplification immunochromatography method 1, as in-vitro diagnostic medical device. This kit has been developed with the use of highly-sensitive detection technology based on silver halide amplification response used in the photo-developing process.